high-risk diabetics in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study, patients randomized to intensive treatment reached a hemoglobin A 1c of 6.4%, and patients randomized to conventional treatment reached a hemoglobin level of 7.5% [8] . At 3.5-year follow-up, intensive therapy increased mortality 22% from 4.0% to 5.0% (p = 0.04) and did not significantly reduce major cardiovascular events.
Obese diabetics with CAD must lose weight by dietary therapy and by aerobic physical activity. They should exercise for at least 30 min daily for 7 days per week with a minimum of 5 days of physical exercise per week [9] .
Diabetics with CAD should be treated with aspirin, ACE inhibitors, β-blockers, and statins to reduce cardiovascular events and mortality and coronary revascularization [6, [9] [10] [11] [12] [13] . Angina pectoris should be treated with β-blockers and nitrates [14] . If angina persists, I would add a calcium channel blocker, and if needed, ranolazine.
In the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, of 2, 248 patients with stable CAD randomized to optimal medical therapy plus percutaneous coronary intervention (PCI) vs. optimal medical therapy alone, 766 patients (34%) had diabetes mellitus, and 1,362 patients (61%) had the metabolic syndrome [15] . At 4.6-year median follow-up, the risk of death or myocardial in infarction in patients with diabetes mellitus and in patients with the metabolic syndrome was similar in patients with and without early PCI. On the basis of these data, I would not recommend early PCI to patients with diabetes mellitus or the metabolic syndrome who have stable CAD.
In the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D ) trial, 2,368 patients with diabetes mellitus and CAD were randomized to undergo either prompt coronary revascularization with intensive medical therapy or intensive medical therapy alone and to undergo either insulin-sensitization or insulin-provision therapy [16] . Randomization was stratified according to the choice of PCI or coronary artery bypass grafting (CABG). At 5-year follow-up, survival was 88.3% for the coronary revascularization group and 87.8% for the medical therapy alone group (p not significant) and 88.2% for the insulin-sensitization group and 87.9% for the insulin-provision group (p not significant). The incidence of freedom from major cardiovascular events was also not significantly different between the coronary revascularization and medical therapy alone groups and between the insulin-sensitization and insulin provision groups. In the PCI stratum, the primary endpoints of death and of death or major cardiovascular events were similar in the PCI and medical therapy alone groups. However, in the CABG stratum, the incidence of death or myocardial infarction or stroke was 22.4% in the CABG group vs. 30.5% in the medical therapy alone group (p = 0.01) [16] .
In the BARI 2 D trial, 1,191 patients were randomized to optimal medical therapy alone and 1,173 patients to coronary revascularization with 796 patients preselected for PCI and 377 patients to CABG [17] . Compared with the medical therapy group alone, at 3-year follow-up, the coronary revascularization group had a lower incidence of worsening angina pectoris (8% vs. 13%, p < 0.001), a lower incidence of new angina pectoris (37% vs. 51%, p = 0.001), a lower incidence of subsequent coronary revascularization (18% vs. 33%, p < 0.001), and a higher incidence of angina-free status (66% vs. 58%, p = 0.003). The CABG patients were at higher risk than the PCI patients and had the greatest benefits from coronary revascularization. The symptomatic benefits were observed particularly for high-risk patients.
These data favor optimal medical therapy alone in patients with diabetes mellitus and stable CAD. However, if disabling angina pectoris despite optimal medical therapy occurs, I would recommend coronary revascularization. In high-risk patients, I would recommend CABG over PCI at this time. At 10.4-year follow-up of diabetics with CAD in the BARI trial, the CABG group had a survival rate of 57.8% vs. 45.5% for the PCI group (p = 0.025) and a subsequent coronary revascularization incidence of 20.3% for the CABG group vs. 76.8% for the PCI group (p < 0.001) [18] .
On the basis of the available data, I would treat patients with diabetes mellitus and ST-segment elevation myocardial infarction [19] or unstable angina/non-ST-segment elevation myocardial infarction [20] with coronary revascularization with the choice of PCI or CABG depending on the coronary angiographic findings. The blood sugar in these patients should have a target goal between 140-180 mg/dl. Diabetics who have received stents should be treated with dual antiplatelet therapy for at least 1 year after PCI and preferably longer.
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